$SAN #Sanofi Sanofi : Results confirming advantages of the class in MS: &gt;New class shaping up in MS - Yesterday, Sanofi disclosed the phase II results for oral SAR442168, its BTK inhibitor, developed for relapsing (and therefore… https://t.co/epfuo9TBuC #equity #stocks https://t.co/HTJ7qcQH6H